Collins Helen Louise
Reporting owner on Forms 3, 4 and 5, CIK 1701247.
Collins Helen Louise reported on 1 issuer in 2 filings, the latest a Form 4 filed 2026-11-19.
Issuers
| Issuer | Roles in the latest filing | Filings | Last filed |
|---|---|---|---|
| ELVN · Enliven Therapeutics, Inc.CIK 1672619 | officer (CHIEF MEDICAL OFFICER) | 2 | 2026-11-19 |
Transactions and holdings
Every row of the person's Forms 3, 4 and 5, newest first, with the price and the amount owned after the row as filed.
| Security | Date | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| ELVN · Enliven Therapeutics, Inc.Common Stock | 2026-11-17 | M exercised | +5,000 | $2.48 | 30,000 | Form 4 |
| ELVN · Enliven Therapeutics, Inc.Common Stock | 2026-11-17 | S sold | -4,939 | $46.8313 | 25,061 | Form 4 |
| ELVN · Enliven Therapeutics, Inc.Common Stock | 2026-11-17 | S sold | -61 | $47.5954 | 25,000 | Form 4 |
| ELVN · Enliven Therapeutics, Inc.Stock Option (right to buy), derivative | 2026-11-17 | M exercised | -5,000 | $0 | 96,268 | Form 4 |
| ELVN · Enliven Therapeutics, Inc.Common Stock | 2026-10-19 | M exercised | +5,000 | $2.48 | 30,000 | Form 4 |
| ELVN · Enliven Therapeutics, Inc.Common Stock | 2026-10-19 | S sold | -5,000 | $38.4684 | 25,000 | Form 4 |
| ELVN · Enliven Therapeutics, Inc.Stock Option (right to buy), derivative | 2026-10-19 | M exercised | -5,000 | $0 | 101,268 | Form 4 |
Filings
The person's Forms 3, 4 and 5, and any 13D or 13G naming it.
| Filing | Subject | Filed | Accepted | Ingested |
|---|---|---|---|---|
| Form 4 0001701247-26-000015 | Enliven Therapeutics, Inc. | 2026-11-19 | ||
| Form 4 0001701247-26-000014 | Enliven Therapeutics, Inc. | 2026-10-21 |